Literature DB >> 23826063

Assessing the cost-benefit relationship in BPH therapy.

Jason Izard1.   

Abstract

Year:  2013        PMID： 23826063      PMCID： PMC3699098          DOI： 10.5489/cuaj.1377

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  8 in total

1.  Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial.

Authors:  Afisi Ismaila; Anna Walker; Amyn Sayani; Bruno Laroche; J Curtis Nickel; John Posnett; Zhen Su
Journal:  Can Urol Assoc J       Date:  2013-06-12       Impact factor: 1.862

2.  Impact of medical therapy on transurethral resection of the prostate: two decades of change.

Authors:  Jason Izard; J Curtis Nickel
Journal:  BJU Int       Date:  2010-09-30       Impact factor: 5.588

3.  Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride.

Authors:  J Barkin; M Guimarães; G Jacobi; D Pushkar; S Taylor; O B van Vierssen Trip
Journal:  Eur Urol       Date:  2003-10       Impact factor: 20.096

Review 4.  Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement.

Authors:  Sascha A Ahyai; Peter Gilling; Steven A Kaplan; Rainer M Kuntz; Stephan Madersbacher; Francesco Montorsi; Mark J Speakman; Christian G Stief
Journal:  Eur Urol       Date:  2010-06-11       Impact factor: 20.096

5.  Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Perinchery Narayan; Christopher P Evans; Timothy Moon
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

6.  Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers.

Authors:  J Curtis Nickel; Jack Barkin; Caroline Koch; Charles Dupont; Mostafa Elhilali
Journal:  Can Urol Assoc J       Date:  2008-02       Impact factor: 1.862

7.  The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.

Authors:  Claus G Roehrborn; Paul Siami; Jack Barkin; Ronaldo Damião; Kim Major-Walker; Indrani Nandy; Betsy B Morrill; R Paul Gagnier; Francesco Montorsi
Journal:  Eur Urol       Date:  2009-09-19       Impact factor: 20.096

8.  Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

Authors:  Claus G Roehrborn; Peter Boyle; J Curtis Nickel; Klaus Hoefner; Gerald Andriole
Journal:  Urology       Date:  2002-09       Impact factor: 2.649
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.